PLK1
Serine/threonine-protein kinase PLK1
As of the edition of 20 October 2026, PLK1 (serine/threonine-protein kinase PLK1, UniProt P53350) has 10 drugs tested at it and 10 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P53350
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 85
- Disease areas
- Cancer; Blood and lymph; Digestive system; Hormones; Immune system; Lungs and airways; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 60
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Went quiet | 5 |
| Stopped | 3 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Volasertib | Went quiet | Phase 3 | none listed |
| Onvansertib | Active | Phase 2 | none listed |
| BI-2536 | Stopped | Phase 2 | none listed |
| TKM-080301 | Went quiet | Phase 2 | none listed |
| CYC140 | Stopped | Phase 2 | none listed |
| Cafusertib | Went quiet | Phase 1 | none listed |
| BAL0891 | Active | Phase 1 | none listed |
| GSK-461364 | Went quiet | Phase 1 | none listed |
| MK-1496 | Went quiet | Phase 1 | none listed |
| TAK-960 | Stopped | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Engaged | 3 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Boehringer Ingelheim | Route A |
| Takeda | Route A |
| Cyclacel Pharmaceuticals | Route A |
The other 7 companies at PLK1
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at PLK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.